Skip to main content
. 2018 Jun 1;13(6):e0198038. doi: 10.1371/journal.pone.0198038

Fig 4. Cytotoxicity (MTT) (mean±SEM) of KAN0439834, gemcitabine and anti-ROR1 mAb in pancreatic cancer cell lines.

Fig 4

(A) KAN0439834 in PaCa-2 cell line was significantly more effective compared to gemcitabine (p = 0.0001). KAN0439834 and gemcitabine in combination induced significantly higher cytotoxicity compared to KAN0439834 or gemcitabine alone (KAN0439834 plus gemcitabine vs KAN0439834, p = 0.0033, KAN0439834 plus gemcitabine vs gemcitabine, p = 0.0001). No statistically significant difference comparing KAN0439834 with KAN0439834 plus anti-ROR1 mAb. (B) Cytotoxicity of Capan-1 cells (KAN0439834 vs gemcitabine, p = 0.0483, KAN0439834 plus gemcitabine vs KAN0439834, p = 0.0029, KAN0439834 plus gemcitabine vs gemcitabine, p = 0.0009, KAN0439834 plus anti-ROR1 CRD mAb vs KAN0439834, p = 0.0039, KAN0439834 plus anti-ROR1 mAb vs anti-ROR1 mAb, p = 0.0001) (C) Cytotoxicity of BxPC-3 cells (KAN0439834 vs gemcitabine, p = 0.0044, KAN0439834 plus gemcitabine vs KAN0439834, p = 0.1481, KAN0439834 plus gemcitabine vs gemcitabine, p = 0.0011, KAN0439834 plus anti-ROR1 mAb vs KAN0439834, p = 0.0034, KAN0439834 plus anti-ROR1 mAb vs anti-ROR1 mAb, p = 0.0001). (D) Cytotoxicity of AsPC-1 cells (KAN0439834 vs gemcitabine, p = 0.0106, KAN0439834 plus gemcitabine vs KAN0439834, p = 0.0010, KAN0439834 plus gemcitabine vs gemcitabine, p = 0.0001, KAN0439834 plus anti-ROR1 mAb vs KAN0439834, p = 0.0007, KAN0439834 plus anti-ROR1 mAb vs anti-ROR1 mAb, p = 0.0001).